Sign in
Taking people in United StatesPhase 2

Testing different doses of GIA632 for non-segmental vitiligo in adults

Tests GIA632 at several doses in adults with non-segmental vitiligo.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Ann Arbor, Bellaire, Birmingham, Fort Gratiot, Fountain Valley, Glenview, Hollywood, Houston, Indianapolis, Jacksonville, Las Vegas, Miami, Murfreesboro, Norfolk, Omaha, Pflugerville, Plano, Portland, Rockville, San Diego, St. Petersburg, The Bronx, Thousand Oaks, and Troy, United StatesSee the 24 sitesAlso in 11 other countries, 61 sites
Trial code
Registry title
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Status
Recruiting
Phase
Phase 2
People taking part
210 people, planned
Started
9 Mar 2026
Expected to end
28 Jan 2030
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • GIA632
  • Placebo
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with non-segmental vitiligo, a condition where the skin loses color in patches. It tests different doses of GIA632 against a placebo (dummy drug).

Age
18 Years to 99 Years
Sex
Male or female as assigned at birth
Disease stage
Non-segmental vitiligo confirmed by the study doctor. Patches must cover ≥ 0.5% of body surface on the face with an F-VASI score ≥ 0.5. Patches must also cover ≥ 3% of body surface outside the face, not counting hands and feet, with a T-VASI score of 3 to 60.
Earlier treatment
People who had biologic drugs aimed at IL-15 or IL-15 receptors cannot join. People who tried or finished depigmentation therapy (removing remaining skin color) for vitiligo cannot join.

Main reasons for not taking part

  • Segmental or mixed vitiligo
  • Other skin conditions that could disturb the study checks, such as hypopigmented mycosis fungoides, piebaldism or chemical- or drug-induced skin color loss
  • Earlier use of biologic drugs aimed at IL-15 or IL-15 receptors
  • Earlier depigmentation therapy for vitiligo
  • Not able or willing to follow study steps or fill in questionnaires

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Signed informed consent must be obtained prior to participation in the study
  • Male or female as assigned at birth ≥ 18 years of age at the time of screening
  • Individuals with a diagnosis of non-segmental vitiligo and confirmation of diagnosis through physical examination by the investigator
  • Non-segmental vitiligo, as assessed at screening, as
  • ≥ 0.5% Body Surface Area (BSA) on the face and F-VASI score ≥ 0.5
  • ≥ 3% BSA on non-facial areas (minimum of 3% should be calculated in addition to hands and feet) and T-VASI score = 3 to 60

Who cannot take part

  • Previous exposure to biologic drugs directly targeting IL-15 or IL-15 receptors
  • Individual who previously attempted or completed depigmentation therapy for NSV
  • Use of prohibited medication \& treatments. Other protocol-defined inclusion/exclusion criteria may apply
  • Presence of segmental or mixed vitiligo, or other skin comorbidities that may interfere with study assessments (e.g., hypopigmented mycosis fungoides, genetic diseases with pigmentary aberrations [such as piebaldism, Waardenburg, etc.], chemical- or druginduced leukoderma, etc.)
  • Individuals unable or unwilling to follow the study procedures and/or to complete the study-related questionnaires

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in United States

Also in 11 other countries, 61 sites

  • Uni Of Michigan Health SystemAnn Arbor, United StatesContact: Nicole MahnTaking people
  • Bellaire Dermatology AssociatesBellaire, United StatesContact: Luis Leal RuizTaking people
  • Cahaba Derm and skin hlth ctr 27Birmingham, United StatesContact: Wes BoothTaking people
  • Hamzavi DermatologyFort Gratiot, United StatesContact: Lee CampbellTaking people
  • First OC DermatologyFountain Valley, United StatesContact: Keiry EspinozaTaking people
  • Endeavor HealthGlenview, United StatesContact: Jalen CoreyTaking people
  • Encore Medical ResearchHollywood, United StatesContact: Yeniska HallTaking people
  • Center for Clinical StudiesHouston, United StatesContact: Perla RivasTaking people
  • Dawes Fretzin Clinical Rea GroupIndianapolis, United StatesContact: Michelle RiggsTaking people
  • Mayo Clinic- JacksonvilleJacksonville, United StatesContact: Jarell C HughesTaking people
  • Las Vegas DermatologyLas Vegas, United StatesContact: Faith LimonTaking people
  • Miami Derm and Laser InstituteMiami, United StatesContact: Swanee CeperoTaking people
  • International Clinical Research Tennessee LCCMurfreesboro, United StatesContact: Eris SteeleTaking people
  • Virginia Clinical ResearchNorfolk, United StatesContact: Crystal TempleTaking people
  • Skin Specialists, PCOmaha, United StatesContact: Schyler SchrieverTaking people
  • Austin Inst for Clinical ResearchPflugerville, United StatesContact: Tolga HanTaking people
  • ACRC TrialsPlano, United StatesContact: Jani TaylorTaking people
  • Oregon Medical Research CenterPortland, United StatesContact: Megan LameyTaking people
  • DermAssociates, LLCRockville, United StatesContact: Meheret AfeworkTaking people
  • MedDerm AssociatesSan Diego, United StatesContact: Kristian CadagTaking people
  • Global Clinical ProfessionalsSt. Petersburg, United StatesContact: Madelaine PerezTaking people
  • Equity MedicalThe Bronx, United StatesContact: Luana CabrejaTaking people
  • Clinical Trials Research InstituteThousand Oaks, United StatesContact: Shawn AhoubimTaking people
  • Revival Research InstituteTroy, United StatesContact: Madhuri ParaTaking people

About the trial

What the trial wants to find out

The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.

The 5 groups in the trial

  • GIA632 Arm 1Treatment being tested

    GIA632 will be administered during the 48-week core period.

    Treatment: GIA632

  • GIA632 Arm 2Treatment being tested

    GIA632 will be administered during the 48-week core period.

    Treatment: GIA632

  • GIA632 Arm 3Treatment being tested

    GIA632 will be administered during the 48-week core period.

    Treatment: GIA632

  • GIA632 Arm 4Treatment being tested

    GIA632 will be administered during the 48-week core period.

    Treatment: GIA632

  • PlaceboPlacebo, for comparison

    Placebo will be administered during the 48-week core period.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period
Plain-language title
Testing different doses of GIA632 for non-segmental vitiligo in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07431177, who can take part
Record updated
9 November 2026